Logo image of SYBX

SYNLOGIC INC (SYBX) Stock Fundamental Analysis

NASDAQ:SYBX - Nasdaq - US87166L2097 - Common Stock - Currency: USD

1.14  -0.02 (-2.06%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SYBX. SYBX was compared to 566 industry peers in the Biotechnology industry. The financial health of SYBX is average, but there are quite some concerns on its profitability. SYBX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SYBX had negative earnings in the past year.
SYBX had a negative operating cash flow in the past year.
In the past 5 years SYBX always reported negative net income.
In the past 5 years SYBX always reported negative operating cash flow.
SYBX Yearly Net Income VS EBIT VS OCF VS FCFSYBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

SYBX's Return On Assets of -277.03% is on the low side compared to the rest of the industry. SYBX is outperformed by 93.64% of its industry peers.
Looking at the Return On Equity, with a value of -430.73%, SYBX is doing worse than 77.74% of the companies in the same industry.
Industry RankSector Rank
ROA -277.03%
ROE -430.73%
ROIC N/A
ROA(3y)-86.19%
ROA(5y)-66.88%
ROE(3y)-150.08%
ROE(5y)-108.55%
ROIC(3y)N/A
ROIC(5y)N/A
SYBX Yearly ROA, ROE, ROICSYBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

SYBX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYBX Yearly Profit, Operating, Gross MarginsSYBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K -250K

More info and screens

5

2. Health

2.1 Basic Checks

SYBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SYBX has more shares outstanding
SYBX has more shares outstanding than it did 5 years ago.
SYBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SYBX Yearly Shares OutstandingSYBX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
SYBX Yearly Total Debt VS Total AssetsSYBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

SYBX has an Altman-Z score of -33.65. This is a bad value and indicates that SYBX is not financially healthy and even has some risk of bankruptcy.
SYBX has a Altman-Z score of -33.65. This is amonst the worse of the industry: SYBX underperforms 91.52% of its industry peers.
There is no outstanding debt for SYBX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.65
ROIC/WACCN/A
WACC9.99%
SYBX Yearly LT Debt VS Equity VS FCFSYBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

SYBX has a Current Ratio of 2.80. This indicates that SYBX is financially healthy and has no problem in meeting its short term obligations.
SYBX has a Current ratio of 2.80. This is in the lower half of the industry: SYBX underperforms 67.14% of its industry peers.
SYBX has a Quick Ratio of 2.80. This indicates that SYBX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.80, SYBX is not doing good in the industry: 65.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.8
SYBX Yearly Current Assets VS Current LiabilitesSYBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

SYBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.93%, which is quite impressive.
The Revenue for SYBX has decreased by -99.53% in the past year. This is quite bad
Measured over the past years, SYBX shows a very negative growth in Revenue. The Revenue has been decreasing by -67.54% on average per year.
EPS 1Y (TTM)76.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.49%
Revenue 1Y (TTM)-99.53%
Revenue growth 3Y-83.4%
Revenue growth 5Y-67.54%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 48.51% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y80.9%
EPS Next 2Y38.08%
EPS Next 3Y-10.72%
EPS Next 5Y48.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SYBX Yearly Revenue VS EstimatesSYBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2027 2028 50M 100M 150M 200M
SYBX Yearly EPS VS EstimatesSYBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SYBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SYBX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYBX Price Earnings VS Forward Price EarningsSYBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYBX Per share dataSYBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A cheap valuation may be justified as SYBX's earnings are expected to decrease with -10.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.08%
EPS Next 3Y-10.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SYBX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNLOGIC INC

NASDAQ:SYBX (4/28/2025, 1:32:50 PM)

1.14

-0.02 (-2.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-12 2025-05-12
Inst Owners64.61%
Inst Owner Change0%
Ins Owners13.48%
Ins Owner Change-0.01%
Market Cap13.34M
Analysts43.33
Price Target1.02 (-10.53%)
Short Float %0.5%
Short Ratio5.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)67.86%
Min EPS beat(2)41.18%
Max EPS beat(2)94.55%
EPS beat(4)3
Avg EPS beat(4)13.91%
Min EPS beat(4)-210.86%
Max EPS beat(4)130.76%
EPS beat(8)6
Avg EPS beat(8)0.47%
EPS beat(12)9
Avg EPS beat(12)1.63%
EPS beat(16)13
Avg EPS beat(16)3.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 833.62
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.05
EV/EBITDA N/A
EPS(TTM)-2.51
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-2.71
FCFYN/A
OCF(TTM)-2.71
OCFYN/A
SpS0
BVpS1.09
TBVpS1.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -277.03%
ROE -430.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.19%
ROA(5y)-66.88%
ROE(3y)-150.08%
ROE(5y)-108.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.03%
Cap/Sales 87.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.8
Altman-Z -33.65
F-Score3
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)14.64%
Cap/Depr(5y)17.39%
Cap/Sales(3y)81.07%
Cap/Sales(5y)70.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.49%
EPS Next Y80.9%
EPS Next 2Y38.08%
EPS Next 3Y-10.72%
EPS Next 5Y48.51%
Revenue 1Y (TTM)-99.53%
Revenue growth 3Y-83.4%
Revenue growth 5Y-67.54%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y52.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.66%
OCF growth 3YN/A
OCF growth 5YN/A